"Recombinant-Alpha 2b Treatment in Patients with Chronic Active Hepatitis: Effects on Peripheral Blood Mononuclear Cells and Correlation with Response."

According to the authors' abstract of an article published in Current Therapeutic Research - Clinical and Experimental, "The purpose of this study was to evaluate the relationship between peripheral blood monocyte and lymphocyte subsets and response to recombinant-alpha 2b-interferon (r-alpha 2b-IFN) in patients with viral chronic active hepatitis (CAH). Peripheral blood mononuclear cell subsets were studied by use of flow cytometry before beginning treatment, after 24 hours, and after 15, 30, and 90 days of treatment with r-alpha 2b-IFN (3 million U thrice weekly) in 16 patients with CAH-11 who tested anti-HCV-positive and five HBsAg-positive/anti-HBe-positive/HBV-DNA-positive...

Want to see the full article?

• Purchase this article for only $3.00